메뉴 건너뛰기




Volumn 10, Issue 1, 2010, Pages 1-11

The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy

Author keywords

Cholesterol; Myopathy; Polymorphism; SLCO1B1; Statin; Transporter

Indexed keywords

ATORVASTATIN; CARRIER PROTEIN; CERIVASTATIN; CYCLOSPORIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METHOTREXATE; MEVINOLIN; ORGANIC ANION TRANSPORTER 2; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

EID: 75549088606     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2009.54     Document Type: Review
Times cited : (143)

References (53)
  • 1
    • 33846857559 scopus 로고    scopus 로고
    • Heart disease and stroke statistics-2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
    • Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69-e171.
    • (2007) Circulation , vol.115
    • Rosamond, W.1    Flegal, K.2    Friday, G.3    Furie, K.4    Go, A.5    Greenlund, K.6
  • 2
    • 22744448612 scopus 로고    scopus 로고
    • HMG-CoA reductase inhibitor pharmacogenomics: Overview and implications for practice
    • Zineh I. HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice. Future Cardiol 2005; 1: 191-206.
    • (2005) Future Cardiol , vol.1 , pp. 191-206
    • Zineh, I.1
  • 3
    • 33746799030 scopus 로고    scopus 로고
    • Clinical implications of pharma-cogenomics of statin treatment
    • Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharma-cogenomics of statin treatment. Pharmacogenomics J 2006; 6: 360-374.
    • (2006) Pharmacogenomics J , vol.6 , pp. 360-374
    • Mangravite, L.M.1    Thorn, C.F.2    Krauss, R.M.3
  • 4
    • 16644386102 scopus 로고    scopus 로고
    • Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors
    • Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 2004; 19: 375-380.
    • (2004) Drug Metab Pharmacokinet , vol.19 , pp. 375-380
    • Tachibana-Iimori, R.1    Tabara, Y.2    Kusuhara, H.3    Kohara, K.4    Kawamoto, R.5    Nakura, J.6
  • 5
    • 26244432388 scopus 로고    scopus 로고
    • Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    • Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
    • (2005) Lancet , vol.366 , pp. 1267-1278
    • Baigent, C.1    Keech, A.2    Kearney, P.M.3    Blackwell, L.4    Buck, G.5    Pollicino, C.6
  • 6
    • 0034723758 scopus 로고    scopus 로고
    • The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
    • Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-467.
    • (2000) Arch Intern Med , vol.160 , pp. 459-467
    • Pearson, T.A.1    Laurora, I.2    Chu, H.3    Kafonek, S.4
  • 7
    • 34447307653 scopus 로고    scopus 로고
    • The broad spectrum of statin myopathy: From myalgia to rhabdomyolysis
    • Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007; 18: 401-408.
    • (2007) Curr Opin Lipidol , vol.18 , pp. 401-408
    • Harper, C.R.1    Jacobson, T.A.2
  • 8
    • 67249111853 scopus 로고    scopus 로고
    • Narrative review: Statin-related myopathy
    • Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009; 150: 858-868.
    • (2009) Ann Intern Med , vol.150 , pp. 858-868
    • Joy, T.R.1    Hegele, R.A.2
  • 9
    • 33645881669 scopus 로고    scopus 로고
    • Statin safety: A systematic review
    • Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97: 52C-60C.
    • (2006) Am J Cardiol , vol.97
    • Law, M.1    Rudnicka, A.R.2
  • 11
    • 35748962429 scopus 로고    scopus 로고
    • The safety of statins in clinical practice
    • Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781-1790.
    • (2007) Lancet , vol.370 , pp. 1781-1790
    • Armitage, J.1
  • 12
    • 33845420011 scopus 로고    scopus 로고
    • Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
    • Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: 565-581.
    • (2006) Clin Pharmacol Ther , vol.80 , pp. 565-581
    • Neuvonen, P.J.1    Niemi, M.2    Backman, J.T.3
  • 14
    • 2042539351 scopus 로고    scopus 로고
    • 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: What's it all about?
    • Kim RB. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about? Clin Pharmacol Ther 2004; 75: 381-385.
    • (2004) Clin Pharmacol Ther , vol.75 , pp. 381-385
    • Kim, R.B.1
  • 15
    • 56149110125 scopus 로고    scopus 로고
    • Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs
    • Maeda K, Sugiyama Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet 2008; 23: 223-235.
    • (2008) Drug Metab Pharmacokinet , vol.23 , pp. 223-235
    • Maeda, K.1    Sugiyama, Y.2
  • 16
    • 22544454498 scopus 로고    scopus 로고
    • Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells
    • Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 2005; 15: 513-522.
    • (2005) Pharmacogenet Genomics , vol.15 , pp. 513-522
    • Kameyama, Y.1    Yamashita, K.2    Kobayashi, K.3    Hosokawa, M.4    Chiba, K.5
  • 17
    • 42149127614 scopus 로고    scopus 로고
    • The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: The contribution of transporting activity changes by SLCO1B1*15
    • Deng JW, Song IS, Shin HJ, Yeo CW, Cho DY, Shon JH et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics 2008; 18: 424-433.
    • (2008) Pharmacogenet Genomics , vol.18 , pp. 424-433
    • Deng, J.W.1    Song, I.S.2    Shin, H.J.3    Yeo, C.W.4    Cho, D.Y.5    Shon, J.H.6
  • 18
    • 36148953896 scopus 로고    scopus 로고
    • Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin
    • Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007; 82: 726-733.
    • (2007) Clin Pharmacol Ther , vol.82 , pp. 726-733
    • Pasanen, M.K.1    Fredrikson, H.2    Neuvonen, P.J.3    Niemi, M.4
  • 19
    • 67650753944 scopus 로고    scopus 로고
    • Genetic polymorphisms of uptake (OATP1B1 1B3) and efflux (MRP2 BCRP) transporters: Implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs
    • Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 2009; 5: 703-729.
    • (2009) Expert Opin Drug Metab Toxicol , vol.5 , pp. 703-729
    • Ieiri, I.1    Higuchi, S.2    Sugiyama, Y.3
  • 20
    • 34548103493 scopus 로고    scopus 로고
    • Role of OATP transporters in the disposition of drugs
    • Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007; 8: 787-802.
    • (2007) Pharmacogenomics , vol.8 , pp. 787-802
    • Niemi, M.1
  • 21
    • 56449116103 scopus 로고    scopus 로고
    • ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin
    • Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008; 84: 457-461.
    • (2008) Clin Pharmacol Ther , vol.84 , pp. 457-461
    • Keskitalo, J.E.1    Kurkinen, K.J.2    Neuvoneni, P.J.3    Niemi, M.4
  • 22
    • 68449085764 scopus 로고    scopus 로고
    • No significant effect of ABCB1 haplotypes on the pharma-cokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin
    • Keskitalo JE, Kurkinen KJ, Neuvonen M, Backman JT, Neuvonen PJ, Niemi M. No significant effect of ABCB1 haplotypes on the pharma-cokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br J Clin Pharmacol 2009; 68: 207-213.
    • (2009) Br J Clin Pharmacol , vol.68 , pp. 207-213
    • Keskitalo, J.E.1    Kurkinen, K.J.2    Neuvonen, M.3    Backman, J.T.4    Neuvonen, P.J.5    Niemi, M.6
  • 23
    • 33750731687 scopus 로고    scopus 로고
    • Role of P-glycoprotein in statin drug interactions
    • Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 2006; 26: 1601-1607.
    • (2006) Pharmacotherapy , vol.26 , pp. 1601-1607
    • Holtzman, C.W.1    Wiggins, B.S.2    Spinler, S.A.3
  • 24
    • 33748042671 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions
    • Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006; 112: 71-105.
    • (2006) Pharmacol Ther , vol.112 , pp. 71-105
    • Shitara, Y.1    Sugiyama, Y.2
  • 25
    • 33750319402 scopus 로고    scopus 로고
    • Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravas-tatin pharmacokinetics
    • Niemi M, Arnold KA, Backman JT, Pasanen MK, Godtel-Armbrust U, Wojnowski L et al. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravas-tatin pharmacokinetics. Pharmacogenet Genomics 2006; 16: 801-808.
    • (2006) Pharmacogenet Genomics , vol.16 , pp. 801-808
    • Niemi, M.1    Arnold, K.A.2    Backman, J.T.3    Pasanen, M.K.4    Godtel-Armbrust, U.5    Wojnowski, L.6
  • 26
    • 34447335619 scopus 로고    scopus 로고
    • Effect of drug transporter genotypes on pravastatin disposition in European-and African-American participants
    • Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG et al. Effect of drug transporter genotypes on pravastatin disposition in European-and African-American participants. Pharmacogenet Genomics 2007; 17: 647-656.
    • (2007) Pharmacogenet Genomics , vol.17 , pp. 647-656
    • Ho, R.H.1    Choi, L.2    Lee, W.3    Mayo, G.4    Schwarz, U.I.5    Tirona, R.G.6
  • 28
    • 33747884712 scopus 로고    scopus 로고
    • Role of BCRP 421C4A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males
    • Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ et al. Role of BCRP 421C4A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 2006; 373: 99-103.
    • (2006) Clin Chim Acta , vol.373 , pp. 99-103
    • Zhang, W.1    Yu, B.N.2    He, Y.J.3    Fan, L.4    Li, Q.5    Liu, Z.Q.6
  • 29
    • 35448946484 scopus 로고    scopus 로고
    • SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavas-tatin in healthy volunteers
    • Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavas-tatin in healthy volunteers. Clin Pharmacol Ther 2007; 82: 541-547.
    • (2007) Clin Pharmacol Ther , vol.82 , pp. 541-547
    • Ieiri, I.1    Suwannakul, S.2    Maeda, K.3    Uchimaru, H.4    Hashimoto, K.5    Kimura, M.6
  • 30
    • 0033601257 scopus 로고    scopus 로고
    • A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutar-yl-CoA reductase inhibitor transporters
    • Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutar-yl-CoA reductase inhibitor transporters. J Biol Chem 1999; 274: 37161-37168.
    • (1999) J Biol Chem , vol.274 , pp. 37161-37168
    • Hsiang, B.1    Zhu, Y.2    Wang, Z.3    Wu, Y.4    Sasseville, V.5    Yang, W.P.6
  • 31
    • 25144450046 scopus 로고    scopus 로고
    • Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport
    • Ito K, Suzuki H, Horie T, Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res 2005; 22: 1559-1577.
    • (2005) Pharm Res , vol.22 , pp. 1559-1577
    • Ito, K.1    Suzuki, H.2    Horie, T.3    Sugiyama, Y.4
  • 32
    • 4644301418 scopus 로고    scopus 로고
    • Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil
    • Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)- mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004; 311: 228-236.
    • (2004) J Pharmacol Exp Ther , vol.311 , pp. 228-236
    • Shitara, Y.1    Hirano, M.2    Sato, H.3    Sugiyama, Y.4
  • 33
    • 0002186061 scopus 로고    scopus 로고
    • Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C (abstract)
    • Brown CDA, Windass A, Bleasby K, Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C (abstract). Atheroscler Suppl 2001; 2: 90.
    • (2001) Atheroscler Suppl , vol.2 , pp. 90
    • Brown, C.D.A.1    Windass, A.2    Bleasby, K.3    Lauffart, B.4
  • 34
    • 33751096467 scopus 로고    scopus 로고
    • SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
    • Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006; 16: 873-879.
    • (2006) Pharmacogenet Genomics , vol.16 , pp. 873-879
    • Pasanen, M.K.1    Neuvonen, M.2    Neuvonen, P.J.3    Niemi, M.4
  • 35
    • 0035929574 scopus 로고    scopus 로고
    • Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European-and African-Americans
    • Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J Biol Chem 2001; 276: 35669-35675.
    • (2001) J Biol Chem , vol.276 , pp. 35669-35675
    • Tirona, R.G.1    Leake, B.F.2    Merino, G.3    Kim, R.B.4
  • 36
    • 25844458977 scopus 로고    scopus 로고
    • Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
    • Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005; 78: 330-341.
    • (2005) Clin Pharmacol Ther , vol.78 , pp. 330-341
    • Lee, E.1    Ryan, S.2    Birmingham, B.3    Zalikowski, J.4    March, R.5    Ambrose, H.6
  • 38
    • 33745031039 scopus 로고    scopus 로고
    • Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population
    • Pasanen MK, Backman JT, Neuvonen PJ, Niemi M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol 2006; 62: 409-415.
    • (2006) Eur J Clin Pharmacol , vol.62 , pp. 409-415
    • Pasanen, M.K.1    Backman, J.T.2    Neuvonen, P.J.3    Niemi, M.4
  • 41
    • 33646536542 scopus 로고    scopus 로고
    • Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics
    • Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006; 130: 1793-1806.
    • (2006) Gastroenterology , vol.130 , pp. 1793-1806
    • Ho, R.H.1    Tirona, R.G.2    Leake, B.F.3    Glaeser, H.4    Lee, W.5    Lemke, C.J.6
  • 42
    • 0036073404 scopus 로고    scopus 로고
    • Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): Allele frequencies in the Japanese population and functional analysis
    • Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 2002; 302: 804-813.
    • (2002) J Pharmacol Exp Ther , vol.302 , pp. 804-813
    • Nozawa, T.1    Nakajima, M.2    Tamai, I.3    Noda, K.4    Nezu, J.5    Sai, Y.6
  • 43
    • 9244254743 scopus 로고    scopus 로고
    • Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C)
    • Iwai M, Suzuki H, Ieiri I, Otsubo K, Sugiyama Y. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 2004; 14: 749-757.
    • (2004) Pharmacogenetics , vol.14 , pp. 749-757
    • Iwai, M.1    Suzuki, H.2    Ieiri, I.3    Otsubo, K.4    Sugiyama, Y.5
  • 44
    • 18644368162 scopus 로고    scopus 로고
    • A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter
    • Michalski C, Cui Y, Nies AT, Nuessler AK, Neuhaus P, Zanger UM et al. A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem 2002; 277: 43058-43063.
    • (2002) J Biol Chem , vol.277 , pp. 43058-43063
    • Michalski, C.1    Cui, Y.2    Nies, A.T.3    Nuessler, A.K.4    Neuhaus, P.5    Zanger, U.M.6
  • 45
    • 33646198187 scopus 로고    scopus 로고
    • Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin
    • Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lutjohann D et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther 2006; 79: 419-426.
    • (2006) Clin Pharmacol Ther , vol.79 , pp. 419-426
    • Igel, M.1    Arnold, K.A.2    Niemi, M.3    Hofmann, U.4    Schwab, M.5    Lutjohann, D.6
  • 46
    • 33749049136 scopus 로고    scopus 로고
    • SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
    • Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006; 80: 356-366.
    • (2006) Clin Pharmacol Ther , vol.80 , pp. 356-366
    • Niemi, M.1    Pasanen, M.K.2    Neuvonen, P.J.3
  • 48
    • 2042469487 scopus 로고    scopus 로고
    • Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics
    • Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004; 75: 415-421.
    • (2004) Clin Pharmacol Ther , vol.75 , pp. 415-421
    • Mwinyi, J.1    Johne, A.2    Bauer, S.3    Roots, I.4    Gerloff, T.5
  • 49
    • 33646205286 scopus 로고    scopus 로고
    • Effects of organic anion transporting polypeptide 1B1 haplotype on pharmaco-kinetics of pravastatin, valsartan, and temocapril
    • Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmaco-kinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 2006; 79: 427-439.
    • (2006) Clin Pharmacol Ther , vol.79 , pp. 427-439
    • Maeda, K.1    Ieiri, I.2    Yasuda, K.3    Fujino, A.4    Fujiwara, H.5    Otsubo, K.6
  • 50
    • 56149115550 scopus 로고    scopus 로고
    • Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacody-namics of repaglinide and nateglinide
    • Kalliokoski A, Backman JT, Neuvonen PJ, Niemi M. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacody-namics of repaglinide and nateglinide. Pharmacogenet Genomics 2008; 18: 937-942.
    • (2008) Pharmacogenet Genomics , vol.18 , pp. 937-942
    • Kalliokoski, A.1    Backman, J.T.2    Neuvonen, P.J.3    Niemi, M.4
  • 51
    • 33748645938 scopus 로고    scopus 로고
    • Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy
    • Takane H, Miyata M, Burioka N, Shigemasa C, Shimizu E, Otsubo K et al. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Hum Genet 2006; 51: 822-826.
    • (2006) J Hum Genet , vol.51 , pp. 822-826
    • Takane, H.1    Miyata, M.2    Burioka, N.3    Shigemasa, C.4    Shimizu, E.5    Otsubo, K.6
  • 52
    • 34548009561 scopus 로고    scopus 로고
    • SLCO1B1 521T-C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients
    • Zhang W, Chen BL, Ozdemir V, He YJ, Zhou G, Peng DD et al. SLCO1B1 521T-C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br J Clin Pharmacol 2007; 64: 346-352.
    • (2007) Br J Clin Pharmacol , vol.64 , pp. 346-352
    • Zhang, W.1    Chen, B.L.2    Ozdemir, V.3    He, Y.J.4    Zhou, G.5    Peng, D.D.6
  • 53
    • 0037031061 scopus 로고    scopus 로고
    • MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial
    • Heart Protection Study Collaborative Group
    • Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
    • (2002) Lancet , vol.360 , pp. 7-22


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.